WO2009020094A1 - 疎水性分子で修飾した抗体 - Google Patents

疎水性分子で修飾した抗体 Download PDF

Info

Publication number
WO2009020094A1
WO2009020094A1 PCT/JP2008/063959 JP2008063959W WO2009020094A1 WO 2009020094 A1 WO2009020094 A1 WO 2009020094A1 JP 2008063959 W JP2008063959 W JP 2008063959W WO 2009020094 A1 WO2009020094 A1 WO 2009020094A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydrophobic molecule
antibody modified
antibody
immunoliposome
modified
Prior art date
Application number
PCT/JP2008/063959
Other languages
English (en)
French (fr)
Inventor
Koji Morita
Takako Niwa
Yuji Kasuya
Kimihisa Ichikawa
Hiroko Yoshida
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Priority to JP2009526447A priority Critical patent/JPWO2009020094A1/ja
Priority to US12/672,861 priority patent/US20110269942A1/en
Priority to EP08792163A priority patent/EP2184355A4/en
Publication of WO2009020094A1 publication Critical patent/WO2009020094A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

本発明は、癌、自己免疫疾患または炎症性疾患に対して治療効果を有するイムノリポソーム製剤または疎水性分子修飾抗体に関する。すなわち、本発明は、デスドメイン含有受容体発現細胞にアポトーシスを誘導可能な抗体を構成成分とするイムノリポソームまたは疎水性分子修飾抗体に関する。
PCT/JP2008/063959 2007-08-09 2008-08-04 疎水性分子で修飾した抗体 WO2009020094A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2009526447A JPWO2009020094A1 (ja) 2007-08-09 2008-08-04 疎水性分子で修飾した抗体
US12/672,861 US20110269942A1 (en) 2007-08-09 2008-08-04 Antibodies modified with hydrophobic molecule
EP08792163A EP2184355A4 (en) 2007-08-09 2008-08-04 WITH A HYDROPHOBIC MOLECULE MODIFIED ANTIBODY

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-208664 2007-08-09
JP2007208664 2007-08-09

Publications (1)

Publication Number Publication Date
WO2009020094A1 true WO2009020094A1 (ja) 2009-02-12

Family

ID=40341326

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2008/063958 WO2009020093A1 (ja) 2007-08-09 2008-08-04 デスドメイン含有受容体発現細胞にアポトーシスを誘導するイムノリポソーム
PCT/JP2008/063959 WO2009020094A1 (ja) 2007-08-09 2008-08-04 疎水性分子で修飾した抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/063958 WO2009020093A1 (ja) 2007-08-09 2008-08-04 デスドメイン含有受容体発現細胞にアポトーシスを誘導するイムノリポソーム

Country Status (8)

Country Link
US (2) US20100209490A1 (ja)
EP (2) EP2177230A4 (ja)
JP (2) JPWO2009020093A1 (ja)
KR (1) KR20100046185A (ja)
CN (1) CN101820913A (ja)
CA (1) CA2695991A1 (ja)
TW (2) TW200914064A (ja)
WO (2) WO2009020093A1 (ja)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100209490A1 (en) * 2007-08-09 2010-08-19 Daiichi Sankyo Company, Limited Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor
JPWO2012093733A1 (ja) * 2011-01-07 2014-06-09 セイコーエプソン株式会社 抗シグナルペプチド抗体の製造方法
EP2480230A4 (en) * 2009-09-24 2015-06-10 Seattle Genetics Inc LIGAND-DRUG CONJUGATES DR5
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
US9370182B2 (en) 2012-05-28 2016-06-21 Toagosei Co., Ltd. Antimicrobial peptide and use thereof
US9480727B2 (en) 2012-10-18 2016-11-01 Toagosei Co. Ltd. Synthetic peptide for inhibiting expression of type 2 TNF receptor and use thereof
JP2020040983A (ja) * 2014-03-31 2020-03-19 ハンミ ファーマシューティカル カンパニー リミテッド 免疫グロブリンＦｃフラグメント結合を用いたタンパク質及びペプチドの溶解度を改善する方法
JP2021512622A (ja) * 2018-02-06 2021-05-20 シアトル チルドレンズ ホスピタル ディー／ビー／エー シアトル チルドレンズ リサーチ インスティテュート フルオレセイン結合エーテルリン脂質（ｆｌ−ｐｌｅ）で標識された腫瘍に対して最適なｔ細胞機能を示すフルオレセイン特異的ｃａｒ
US11168109B2 (en) 2012-03-08 2021-11-09 Hanmi Science Co., Ltd. Process for preparation of physiologically active polypeptide complex
WO2022136939A1 (en) * 2020-12-21 2022-06-30 Samarth Zarad A method for preparation of a drug encapsulated liposome in an organic solvent emulsion
US11434271B2 (en) 2011-11-04 2022-09-06 Hanmi Science Co., Ltd. Method for preparing physiologically active polypeptide complex

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993715B2 (en) 2009-07-06 2015-03-31 Canon Kabushiki Kaisha Labeled protein and method for obtaining the same
CA2848173C (en) * 2011-05-10 2019-07-02 The Penn State Research Foundation Ceramide anionic liposome compositions
EP2706988B1 (en) * 2011-05-12 2019-12-04 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Liposomes comprising polymer-conjugated lipids and related uses
WO2013155487A1 (en) 2012-04-12 2013-10-17 Yale University Vehicles for controlled delivery of different pharmaceutical agents
TW201417817A (zh) * 2012-09-25 2014-05-16 Daiichi Sankyo Co Ltd Ｇｓｋ３抑制劑與抗ｄｒ５抗體之組合
TWI585101B (zh) * 2012-11-16 2017-06-01 財團法人農業科技研究院 製備抗體Ｆ（ａｂ’）２片段之方法
US9884026B2 (en) 2013-11-01 2018-02-06 Yale University Modular particles for immunotherapy
US11299528B2 (en) 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
EP3116480A1 (en) * 2014-03-12 2017-01-18 GlaxoSmithKline Biologicals S.A. Immunogenic liposomal formulation
US20180161272A1 (en) * 2015-05-26 2018-06-14 The General Hospital Corporation Liposomal nanoconstructs and methods of making and using the same
CA3008392C (en) 2015-12-17 2021-11-09 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
EA201892260A1 (ru) 2016-04-07 2019-03-29 Дзе Джонс Хопкинс Юниверсити Композиции и способы для лечения панкреатита и боли с применением агонистов рецептора смерти
AU2018219226A1 (en) 2017-02-07 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
CN110582288A (zh) 2017-02-28 2019-12-17 恩多塞特公司 用于car t细胞疗法的组合物和方法
US11260132B2 (en) * 2017-03-16 2022-03-01 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
EP3665480A4 (en) * 2017-08-09 2021-05-12 The Regents Of The University Of Michigan STRUCTURES FOR IMITATING APOPTOSIS
CN107753434B (zh) * 2017-12-06 2019-11-05 西南交通大学 一种包载亲疏水性不同药物的载药脂质体及其制备方法与应用
US11779602B2 (en) 2018-01-22 2023-10-10 Endocyte, Inc. Methods of use for CAR T cells
EP3759229A4 (en) * 2018-02-26 2021-12-29 IGM Biosciences Inc. Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
JP2022525924A (ja) * 2019-03-21 2022-05-20 コディアック バイオサイエンシーズ， インコーポレイテッド 細胞外小胞コンジュゲート及びその使用
IT202000004846A1 (it) * 2020-03-06 2021-09-06 Univ Degli Studi G Dannunzio Chieti Pescara Pro-drug innovativo micellare su backbone polimerico del Killer TNF-apoptosis induced ligand.
IT202000013042A1 (it) * 2020-06-01 2021-12-01 Univ Degli Studi G Dannunzio Chieti Pescara Sistema liposomiale con killer tnf-apoptosis induced ligand (killertrail), pro-apoptotico-direzionante.
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
US20230302154A1 (en) * 2020-08-19 2023-09-28 The Board Of Regents Of The University Of Texas System Nanodrugs for targeted drug delivery and use thereof
CN114150007B (zh) * 2021-12-14 2023-07-21 扬州大学 一种适用于家兔乳腺特异性表达去氨普酶的编码基因及其应用
WO2023204290A1 (ja) * 2022-04-21 2023-10-26 愛知県 多重特異性ナノ粒子
CN115181720B (zh) * 2022-07-27 2023-06-30 天津鸿宇泰生物科技有限公司 一种无血清培养基及其应用、一种cho细胞表达重组抗体的构建方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005056605A1 (ja) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha ３量体以上の受容体を認識する改変抗体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
JPH09110722A (ja) * 1995-10-20 1997-04-28 Toray Ind Inc 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6972323B1 (en) * 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
ES2366100T3 (es) * 1999-02-22 2011-10-17 Georgetown University Inmunoliposomas dirigidos mediante un fragmento de anticuerpo para la administración sistémica de genes.
DE10003653A1 (de) * 2000-01-28 2001-08-09 Thorsten Petrich Vektorkonstrukte zur gentherapeutisch vermittelten Radioiodtherapie entdifferenzierter und medullärer Schilddrüsen-Karzinome sowie nicht-thyreoidaler Tumore und ihrer Metastasen
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
EP1537858A1 (en) * 2003-12-04 2005-06-08 Vectron Therapeutics AG Drug delivery vehicles and uses thereof
AU2005282440A1 (en) * 2004-09-08 2006-03-16 Genentech, Inc. Methods of using death receptor ligands and CD20 antibodies
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
MX2007013200A (es) * 2005-04-22 2008-03-24 Johnson & Johnson Composicion de inmunoliposoma para el direccionamiento hacia un receptor de la celula her2.
CA2625951A1 (en) * 2005-09-01 2007-03-08 National Research Council Of Canada Anti-apoptotic protein antibodies
CN101820913A (zh) * 2007-08-09 2010-09-01 第一三共株式会社 在表达含死亡结构域的受体的细胞中诱导细胞凋亡的免疫脂质体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005056605A1 (ja) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha ３量体以上の受容体を認識する改変抗体

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HUWYLER J. ET AL.: "Brain drug delivery of small molecules using immunoliposomes.", PROC.NATL.ACAD.SCI.USA, vol. 93, no. 24, 1996, pages 14164 - 14169, XP002660204 *
KASAOKA S. ET AL.: "Stealth liposome for delivery system.", MEMBRANE, vol. 28, no. 3, 2003, pages 135 - 144, XP008036877 *
MATSUMURA Y. ET AL.: "DDS in cancer chemotherapy.", BIOTHERAPY, vol. 18, no. 4, 2004, Tokyo, pages 339 - 351, XP003000518 *
MILLSTEIN ET AL., NATURE, vol. 305, 61119, pages 537 - 539
MOTOKI K. ET AL.: "Preparation of anti TRAIL-R human antibodies from KM mouse and its application for cancer therapy.", GEKKAN MEDICAL SCIENCE DIGEST, vol. 31, no. 13, 2005, pages 530 - 534 *
OHTSUKI M. ET AL.: "Kandokusei o Shimesanai Shinkiko Fas Kotai HFE7A the 2nd report in vitro Apoptosis Yudo Koka", THE JAPANESE SOCIETY FOR IMMUNOLOGY GAKUJUTSU SHUKAI KIROKU, vol. 28, 1998, pages 293, 4 - A5-159 *
See also references of EP2184355A4

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110269942A1 (en) * 2007-08-09 2011-11-03 Daiichi Sankyo Company, Limited Antibodies modified with hydrophobic molecule
US20100209490A1 (en) * 2007-08-09 2010-08-19 Daiichi Sankyo Company, Limited Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor
EP2480230A4 (en) * 2009-09-24 2015-06-10 Seattle Genetics Inc LIGAND-DRUG CONJUGATES DR5
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
US9309307B2 (en) 2011-01-07 2016-04-12 Seiko Epson Corporation Antibody against amyloid precursor protein signal peptide
JP5855583B2 (ja) * 2011-01-07 2016-02-09 セイコーエプソン株式会社 抗シグナルペプチド抗体の製造方法
JPWO2012093733A1 (ja) * 2011-01-07 2014-06-09 セイコーエプソン株式会社 抗シグナルペプチド抗体の製造方法
US11434271B2 (en) 2011-11-04 2022-09-06 Hanmi Science Co., Ltd. Method for preparing physiologically active polypeptide complex
US11168109B2 (en) 2012-03-08 2021-11-09 Hanmi Science Co., Ltd. Process for preparation of physiologically active polypeptide complex
US9370182B2 (en) 2012-05-28 2016-06-21 Toagosei Co., Ltd. Antimicrobial peptide and use thereof
US9480727B2 (en) 2012-10-18 2016-11-01 Toagosei Co. Ltd. Synthetic peptide for inhibiting expression of type 2 TNF receptor and use thereof
JP2020040983A (ja) * 2014-03-31 2020-03-19 ハンミ ファーマシューティカル カンパニー リミテッド 免疫グロブリンＦｃフラグメント結合を用いたタンパク質及びペプチドの溶解度を改善する方法
JP2021512622A (ja) * 2018-02-06 2021-05-20 シアトル チルドレンズ ホスピタル ディー／ビー／エー シアトル チルドレンズ リサーチ インスティテュート フルオレセイン結合エーテルリン脂質（ｆｌ−ｐｌｅ）で標識された腫瘍に対して最適なｔ細胞機能を示すフルオレセイン特異的ｃａｒ
WO2022136939A1 (en) * 2020-12-21 2022-06-30 Samarth Zarad A method for preparation of a drug encapsulated liposome in an organic solvent emulsion

Also Published As

Publication number Publication date
EP2184355A4 (en) 2011-04-27
TW200916477A (en) 2009-04-16
TW200914064A (en) 2009-04-01
CN101820913A (zh) 2010-09-01
JPWO2009020094A1 (ja) 2010-11-04
EP2177230A4 (en) 2011-04-27
CA2695991A1 (en) 2009-02-12
KR20100046185A (ko) 2010-05-06
WO2009020093A1 (ja) 2009-02-12
EP2184355A1 (en) 2010-05-12
US20100209490A1 (en) 2010-08-19
JPWO2009020093A1 (ja) 2010-11-04
EP2177230A1 (en) 2010-04-21
US20110269942A1 (en) 2011-11-03

Similar Documents

Publication Publication Date Title
WO2009020094A1 (ja) 疎水性分子で修飾した抗体
LTC2170959I2 (lt) Antikūnai prieš žmogaus užprogramuotą mirties receptorių PD-1
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
HRP20150485T1 (en) ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15
EP2379594B8 (en) Human cgrp receptor binding antibodies
FI20075687A0 (fi) Kaksoisantenni
AU2008225994B2 (en) Monoclonal human tumor-specific antibody
BRPI0813448A2 (pt) Combinações de pesticidas.
EP2135075B8 (en) Whole blood assay
BRPI0818865A2 (pt) Anticorpos monoclonais contra proteína c ativada.
HK1137037A1 (en) Cancerous disease modifying antibodies
NL2001260A1 (nl) Tweeband-antenne.
NL2002173A1 (nl) Synthetic Aviation Fuel.
BRPI0715544A2 (pt) Anticorpos que modificam doença cancerosas.
ZA200905063B (en) Cancerous disease modifying antibodies
IL199667A0 (en) Cancerous disease modifying antibodies
FI20075046A0 (fi) Nesteantenni, jossa on vuodonkestävä rakenne
NL2002066A1 (nl) Trailer.
BRPI0816181A2 (pt) Anticorpos modificadores de doença cancerígena.
EP2144997A4 (en) ANTIBODIES MODIFYING CANCER DISEASES
BRPI0718609A2 (pt) Anticorpos modificadores de doença cancerosa.
AU2007321664A8 (en) Cancerous disease modifying antibodies
AU2008258879C1 (en) Fungicidal substance combinations
AU2007903615A0 (en) Reconfigurable trailer assembly
ES1064596Y (es) Calzado con caña desmontable.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08792163

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009526447

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008792163

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12672861

Country of ref document: US